linjc16/ctgov huggingface dataset:
Diffusion Imaging in Acute Auto-immune Encephalitis

Study Overview
=================
Brief Summary
-----------------
The aim of this non randomised retrospective study is to investigate the imaging (MRI) of auto-immune encephalitis at presentation, especially in diffusion-weighted sequences. Indeed, few series describe the MRI aspect of auto-immune at their beginning. Recognize early MRI abnormalities seen in auto-immune encephalitis could help reduce the time to positive diagnosis and improve the therapeutic management.

Official Title
-----------------
Diffusion Imaging in Acute Auto-immune Encephalitis : a Cohort of 80 Patients

Conditions
-----------------
Auto-immune Encephalitis

Intervention / Treatment
-----------------
* Other: Analysis of every MRI at presentation of the symptoms and then over a period of 3 to 24 months if available.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Auto-immune encephalitis proved by biological results (blood and/or CSF sample) Exclusion Criteria: No MRI available
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Analysis of every MRI at presentation of the symptoms and then over a period of 3 to 24 months if available.|The radiologist will analyze the MRI of patients with proved auto-immune encephalitis realized at presentation of the symptoms. If available, the following-up MRIs will also be analyzed. At each assessment, four MRI sequences will be studied : diffusion, T2-weighted, susceptibility sensitive sequences, and T1 weighted after contrast enhanced with gadolinium. The radiologist will analyse the signal abnormalities, their localisation and the trophicity of the brain. We will then correlate the following clinical data collected for patients : age, sex, clinical presentation, clinical evolution, and tumor associated or not.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MRI characterization, especially in Diffusion-weighted magnetic resonance imaging (DWI-MRI), of auto-immune encephalitis at presentation. | The radiologist will analyze the MRI of patients with proved auto-immune encephalitis realized at presentation of the symptoms. If available, the following-up MRIs will also be analyzed. At each assessment, four MRI sequences will be studied : diffusion, T2-weighted, susceptibility sensitive sequences, and T1 weighted after contrast enhanced with gadolinium. The radiologist will analyse the signal abnormalities, their localisation and the trophicity of the brain. We will then correlate the following clinical data collected for patients : age, sex, clinical presentation, clinical evolution, and tumor associated or not. | at following-up until 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MRI
Use of a Training Video to Teach Medical Students About Health Literacy

Study Overview
=================
Brief Summary
-----------------
Briefly describe the purpose of this protocol: This study is designed to evaluate the effectiveness of an educational training video on the topic of health literacy for medical students. Briefly summarize how participants are recruited: OHSU medical students attending mandatory trainings on the topic of health literacy during the 1st and 2nd years of medical school will be invited to participate in the study. Briefly describe the procedures subjects will undergo: Completion of a short self-administered anonymous survey before and after viewing a 23-minute video about health literacy. If applicable, briefly describe survey/interview instruments used: A 12-item pre-test questionnaire and 13-item post-test questionnaire designed to assess individuals' knowledge about health literacy, and intended clinical practices with respect to health literacy. If this is a clinical trial using an experimental drug and/or device, or an approved drug and/or device used for an unapproved purpose, briefly describe the drug and/or device: n/a Briefly describe how the data will be analyzed to address the purpose of the protocol: Demographics and responses to individual items will be reported as frequencies and percentages within the sample. The investigators will use a chi-square analysis to stratify responses by demographic groups and t-tests to measure possible changes over time.

Official Title
-----------------
Use of a Training Video to Teach Medical Students About Health Literacy

Conditions
-----------------
Health Literacy

Intervention / Treatment
-----------------
* Behavioral: health literacy training video


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1st-year medical student at OHSU Exclusion Criteria:
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: training intervention<br>Students participating in didactic training | Behavioral: health literacy training video<br>* participants will watch a training video<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in knowledge | The investigators will measure knowledge about health literacy before and after an educational intervention | immediately following the intervention, and at 12-month follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
curriculum, training, Medical student Knowledge
Efficacy and Safety of Cyclosporine Microemulsion in Diabetic Adult Stable Liver Transplant Recipients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the switch from tacrolimus to cyclosporine microemulsion benefits post-transplant diabetes management (in terms of glycogenic control and insulin dosage) in stable liver transplant recipients.

Official Title
-----------------
Switch From Tacrolimus to Cyclosporine Microemulsion: Immunosuppressive Agents and Diabetes Management in Liver Transplant Recipients in Maintenance (DIALIVER)

Conditions
-----------------
Liver Transplant

Intervention / Treatment
-----------------
* Drug: Cyclosporine microemulsion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 4 months post-transplant Patients in treatment with tacrolimus Post-transplant diabetes treated with insulin for at least one month Exclusion Criteria Known hypersensitivity to cyclosporine microemulsion Investigational drug within 60 days before baseline or during the study Patients who cannot comply with the study requirements Other protocol-defined exclusion criteria applied

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Cyclosporine microemulsion|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adults, Post transplant diabetes
Placental Insufficiency Microcirculation Quantification by Ultrafast Doppler (MICRODOPPLER PLACENTA)

Study Overview
=================
Brief Summary
-----------------
To identify fetuses small for their gestational-age who have reached their appropriate growth potential from growth-restricted fetuses due to placental insufficiency is uneasy. Intra Uterine Growth Restriction (IUGR) increases the risk for indicated preterm delivery, neonatal mortality and morbidity. Therefore, improving the knowledge of the placental perfusion is essential to better identify and manage fetal chronic oxygen deprivation associated with placental insufficiency. Thus, the investigators propose to study placental microcirculation with a more efficient Doppler than conventional Doppler use in clinical practice. The Ultrafast Doppler is being able to map placental blood flow and could have potential impact in placental insufficiency diagnosis and prevention. Moreover, this Doppler could discriminate maternal and fetal vascularization. The hypothesis is that Ultrafast Doppler could help clinician to diagnose and manage preeclampsia and IUGR during pregnancy.

Official Title
-----------------
Placental Insufficiency Microcirculation Quantification by Ultrafast Doppler: an Observational Prospective Study

Conditions
-----------------
Preeclampsia and Intrauterine Growth Restriction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient who accepted to participate in the study Woman over 18 years old Affiliated to a social security scheme Mono-fetal pregnancy Patients with normal pregnancy between 11 and 42 weeks of amenorrhea Patients hospitalized for preeclampsia and / or intrauterine growth retardation, beyond 20 weeks of amenorrhea Exclusion Criteria: Minors, adults under guardianship, protected persons Not affiliated to a social security scheme Multiple pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Qualitative analysis (velocities) of intraplacental blood flow after acquisition of sequences in Ultrafast Doppler imaging |  | from the 12 week of gestation | 
| Quantitative analysis (flow rates) of intraplacental blood flow after acquisition of sequences in Ultrafast Doppler |  | from the 12 week of gestation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
microDoppler, placenta, preeclampsia, intrauterine growth restriction
Mirtazapine in Alzheimer-associated Weight Loss

Study Overview
=================
Brief Summary
-----------------
Weight loss is a frequent problem associated with Alzheimers disease (AD). Mirtazapine has weight loss as a frequent side effect. The aim of this retrospective study is to check whether mirtazapine 30 mg (once daily) can counteract weight loss in patients with AD or mixed dementia (AD + vascular).

Official Title
-----------------
Mirtazapine in Alzheimer-associated Weight Loss: a Retrospective Phase IV Study

Conditions
-----------------
Alzheimer's Disease, Weight Loss, Mixed Dementia, Dementia

Intervention / Treatment
-----------------
* Drug: mirtazapine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: AD or mixed dementia documented weight loss mirtazapine 30 mg explicitly prescribed against weight loss Exclusion Criteria: no treatment compliance other causes of weight loss other interventions against weight loss
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: mirtazapine|30 mg at bedtime|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| body weight |  | 6 months |
Self Efficacy, Walking Ability, Gait Speed and Physical Activity in People With Chronic Lung Disease

Study Overview
=================
Brief Summary
-----------------
Most patients with chronic lung disease underestimate their actual walking ability due to low confidence. To better understand the relationships between lung function, self-efficacy for walking (confidence in ability to walk a defined distance), actual walking ability for the same distance gait speed and physical activity level-PAL- (total energy expenditure/resting metabolic rate). Quality of life, self efficacy for activity questionnaires, physical activity level measurement, 4-meter gait speed and 6-minute walk distance will be measured.

Official Title
-----------------
Determining the Relationships Between Self-efficacy for Walking Ability, Gate Speed and Physical Activity in Patients With Chronic Lung Disease

Conditions
-----------------
Chronic Lung Disease, Self-efficacy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women 40 years and older Diagnosis of any chronic lung disease as evidenced by pulmonary function testing completed within the prior 12 months Able to walk independently and successfully complete the 6-minute walk assessment Exclusion Criteria: Unable to walk without assistance or complete the 6-minute walk assessment Patients unable to comprehend and accurately respond to the study questionnaires either by written or spoken communication Patients diagnosed with or treated for a lower respiratory tract infection or COPD exacerbation within the prior 30 days

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analyze associations between self-efficacy for walking, gait speed, physical activity level and perceptions of symptoms in patient with chronic lung disease (COPD and Pulmonary Fibrosis) | Correlation , regression models and mediation analysis (self efficacy and physical activity) will be performed. | Day of enrollment. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Predictive utility of 4-meter gait speed for estimating physical activity level (PAL) as validated by gold standard activity monitor. | Measure 4-meter gait speed during standardized 6 mintute walk test and compare to armband activity monitor results to determine predictive ability, if any, on PAL in people with chronic lung disease. | 1 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Lung Disease, Exercise, Self-efficacy
Reduction of Zygomatic Arch in Zygomaticomaxillary Fractures

Study Overview
=================
Brief Summary
-----------------
To compare between ultrasound guided closed reduction and open reduction of zygomatic arch in cases of zygomaticomaxillary fracture. To evaluate the role of intra-operative ultrasound during zygomatic arch reduction. To compare between esthetic appearance, orbital movement, wound healing, scaring, and postoperative ocular complications in both groups.

Official Title
-----------------
Ultrasound Guided Closed Reduction Versus Open Reduction of Zygomatic Arch in Zygomaticomaxillary Fractures

Conditions
-----------------
Zygomatic Arch Reduction

Intervention / Treatment
-----------------
* Procedure: reduction of zygomatic arch in zygomaticomaxillary complex fracture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients presenting with ZMC fractures that require reduction and fixation Patients between 20 to 50 years old with no gender predilections Exclusion Criteria: Existence of infection at the fracture line Chronic systemic diseases such as metabolic bone disease, immunocompromised status

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: study (ultrasound guided closed reduction of zygomatic arch))<br>reduction of zygomatic arch guided by ultrasound | Procedure: reduction of zygomatic arch in zygomaticomaxillary complex fracture<br>* ultrasound guided reduction of zygomatic arch<br>* Other names: open reduction of zygomatic arch in zygomaticomaxillary complex fracture;|
| Active Comparator: control (open reduction of zygomatic arch)<br>open reduction of zygomatic arch through coronal incision | Procedure: reduction of zygomatic arch in zygomaticomaxillary complex fracture<br>* ultrasound guided reduction of zygomatic arch<br>* Other names: open reduction of zygomatic arch in zygomaticomaxillary complex fracture;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| zygomatic arch reduction | to measure the amount of zygomatic arch reduction on postoperative ct scan and compare it with the normal side | immediate post operative CT scan |
Notation Optimization Through Template Engineering

Study Overview
=================
Brief Summary
-----------------
This is a randomized non-blinded controlled trial of a standard note template versus a redesigned note template using a simulated patient encounter and the electronic medical record.

Detailed Description
-----------------
Residents documented the simulated patient encounter using one of two templates. The standard template was based on the usual outpatient progress note. The new template placed the assessment and plan section in the beginning, grouped subjective data into the assessment section, and deemphasized elements not related to the current presentation.

Official Title
-----------------
Notation Optimization Through Template Engineering

Conditions
-----------------
Clinical Documentation

Intervention / Treatment
-----------------
* Other: New progress note template
* Other: Standard progress note template


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Residents who had open visit slots during their outpatient clinic time Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Standard template<br>Usual outpatient progress note with standard Subjective Objective Assessment Plan (SOAP) format | Other: Standard progress note template<br>* Residents assigned to document with standard progress note template<br>|
| Experimental: New template<br>The assessment and plan section is placed in the beginning, subjective data grouped into the assessment section, and elements not related to the current presentation were deemphasized | Other: New progress note template<br>* Residents assigned to document with new progress note template<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Note length | Note length in line count. | Duration of note entry, up to 2 hours | 
| Time to note completion | Time to note completion in minutes. | Duration of note entry, up to 2 hours | 
| Note evaluation by authors using a likert scale | Likert-scale survey instrument evaluating perceived organization, structure, and efficiency of note. | Immediately after note entry, up to 1 hour | 
| Note evaluation by reviewers using the Physician Documentation Quality Instrument | Physician Documentation Quality Instrument (PDQI-9) - validated note quality scale composed of 9 metrics. 1 is not at all. 5 is extremely. | Within 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Progress note, Note template, Electronic medical record, Note quality
Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology Associated to Alcoholism

Study Overview
=================
Brief Summary
-----------------
Alcohol dependent patients show comorbid psychiatric symptoms, related to malfunction of dopamine, norepinephrine and serotonin neurotransmission, during early recovery. Ziprasidone can improve malfunctioning of these disregulated systems, thereby improving anxiety, depression, anhedonia, anger, and alcohol craving.

Detailed Description
-----------------
60 alcohol-dependent patients will be included, once finished alcohol detoxification treatment.Thirty patients will receive ziprasidone treatment, in progressively increasing doses, starting from 40 mg per day, and the other 30 patients will receive placebo, in a double blind procedure

Official Title
-----------------
Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology, Not Being a Severe Mental Disorder, Associated to Alcohol Dependence Disorder.

Conditions
-----------------
Depression, Anger, Anxiety, Alcoholism

Intervention / Treatment
-----------------
* Drug: Treatment of psychiatric symptoms associated to alcoholism


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: DSM-IV-TR criteria for alcohol dependence disorder Age between 18 -65 years old. Score 7 or higher in the GHQ-28 scale. Exclusion Criteria: More than 30 days without drinking alcohol. Severe medical disorders. Psychotic or bipolar disorders severely decompensated requiring antipsychotic medication. Opiate, cocaine or benzodiazepine dependence disorders, requiring more than one week of detoxification treatment. Pregnant or lactating women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Treatment of psychiatric symptoms associated to alcoholism|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Score opf SCL-90-R psychiatric symptoms scale. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Alcohol consumption (amount and frequency) |  |  | 
| Alcohol craving |  |  | 
| Other substances consumption |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Psychiatric symptoms associated to alcoholism recovery, Alcoholism treatment, Alcohol craving, Relapse to heavy drinking, Abuse of other substances during alcoholism recovery